Celgene
celgene.comTotal trials
478
Active
24
Phase 3
86
Total enrollment
93,192
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 50 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Cyclophosphamide | — | — | — | 11 | |||
| Dexamethasone | — | — | 37 | ||||
| Rituximab | — | — | — | 20 | |||
| Bortezomib | — | — | 9 | ||||
| Daratumumab | — | — | — | — | 8 | ||
| Vincristine | — | — | — | 8 | |||
| Doxorubicin | — | — | — | 6 | |||
| Prednisone | — | — | — | 11 | |||
| Carfilzomib | — | — | — | — | 4 | ||
| Golcadomide | — | — | — | 4 | |||
| Lenalidomide | — | — | 58 | ||||
| Fludarabine | — | — | — | 4 | |||
| Bendamustine | — | — | — | — | 4 | ||
| BMS-986365 | — | — | — | — | 4 | ||
| Mezigdomide | — | — | — | 4 | |||
| Elotuzumab | — | — | — | — | 3 | ||
| ACE-536 | — | — | — | — | 2 | ||
| Pomalidomide | — | — | 30 | ||||
| Azacitidine | — | 18 | |||||
| Luspatercept | — | — | — | 9 | |||
| Romidepsin | — | — | — | 10 | |||
| bb2121 | — | — | — | 6 | |||
| Docetaxel | — | — | — | — | 3 | ||
| Iberdomide | — | — | — | — | 2 | ||
| Abiraterone | — | — | — | — | 2 | ||
| Ixazomib | — | — | — | — | — | 1 | |
| idecabtagene vicleucel | — | — | — | — | — | 1 | |
| Prednisone/Prednisolone | — | — | — | — | — | 1 | |
| Enzalutamide | — | — | — | — | — | 1 | |
| Predinsone/Prednisolone | — | — | — | — | — | 1 | |
| Gene-modified (GM) T cell therapy | — | — | — | — | — | 1 | |
| Epoetin alfa | — | — | — | — | — | 1 | |
| Gemcitabine | — | — | 14 | ||||
| CC-220 | — | — | — | — | 14 | ||
| CC-99282 | — | — | — | — | 4 | ||
| BMS-986368 | — | — | — | — | 4 | ||
| JCAR017 | — | — | — | — | 5 | ||
| Obinutuzumab | — | — | — | — | 5 | ||
| CC-92480 | — | — | — | — | 5 | ||
| Tafasitamab | — | — | — | — | — | 2 |
10 more active programs hidden
Next readouts
- 2018-08-02
- 2021-02-10
- 2023-03-31
- 2024-05-09
- 2025-05-26
- 2025-08-11
- 2026-06-14
- 2026-11-23
- 2026-11-30
- 2027-01-10
Top conditions
- Multiple Myeloma97
- Healthy Volunteers38
- Myelodysplastic Syndromes33
- Leukemia, Myeloid, Acute16
- Lymphoma, Non-Hodgkin16
- Neoplasms12
- Healthy Volunteer12
- Myelodysplastic Syndrome11
Frequently asked questions about Celgene
- How many clinical trials does Celgene have on ClinicalTrials.gov?
- Celgene is listed as the lead sponsor on 478 clinical trials in ClinicalTrials.gov, 24 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Celgene's trials are in Phase 3?
- 86 of Celgene's trials are in Phase 3, spread across 50 active drug programs.
- What therapeutic areas does Celgene focus on?
- Celgene's most-studied conditions on ClinicalTrials.gov are Multiple Myeloma, Healthy Volunteers, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin.
- When are Celgene's next clinical trial readouts?
- Celgene has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy”, expected around 2018-08-02.